Habib Bennaceur: NNHF Strengthens Haemophilia and Haemoglobinopathy Care Worldwide
Habib Bennaceur, Senior Vice President of Rare Disease Unit at Novo Nordisk, shared Novo Nordisk Haemophilia and Haemoglobinopathies Foundation‘s post on LinkedIn:
“Since 2005, the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation (NNHF) has worked with local partners to strengthen care worldwide, supporting 265 projects across 88 countries to date.
In the first half of 2026, NNHF:
- Added five new projects to its global portfolio.
- Advanced its collaboration with Africa Centres for Disease Control and Prevention (Africa CDC) to support stronger policies, diagnosis and access to care across Africa.
- Strengthened local capacity, with 345+ healthcare professionals trained across India, Mozambique and Venezuela, alongside many more activities across countries and regions.
As President of the NNHF, I am proud to see this progress taking shape across our programmes.
To all NNHF partners, thank you for your ongoing commitment!
Discover more in the First-half 2026 Programme Report.”
Novo Nordisk Haemophilia and Haemoglobinopathies Foundation shared a post on LinkedIn:
“What does progress look like?
Progress takes many forms: improved diagnosis, stronger care systems, and knowledge and expertise shared across borders.
During the first half of 2026:
Stronger diagnosis and care
In Mozambique, more than 180 healthcare professionals, including laboratory technicians, received haemophilia training, helping strengthen diagnosis, referral pathways and access to multidisciplinary care closer to home for people living with haemophilia.
Stronger systems of care
In Nigeria, the Inherited Blood Disorders Leadership Forum brought together 74 stakeholders and led to the establishment of a Technical Working Group for sickle cell disease, haemophilia and other inherited blood disorders.
Knowledge and expertise shared across borders
Across East Africa, West Francophone Africa, Central America and the Caribbean, Portuguese-speaking Africa and the Vanilla Islands, partners are connecting within their regions to share expertise and strengthen approaches to care.
These examples are only a snapshot of the developments featured in our First-half 2026 Programme Report.”

Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?